Your shopping cart is currently empty

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $432 | - | In Stock |
| Description | ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. |
| Targets&IC50 | CXCR4:194 nM(EC50) |
| In vitro | ATI-2341 induces CXCR4- and G protein-dependent signaling, receptor internalization, and chemotaxis in CXCR4-expressing cells, with an EC50 value of 194 ± 16 nM and intrinsic activity of 81 ± 4%. It is a potent mobilizer of bone marrow PMNs (polymorphonuclear neutrophils) and HSPCs (hematopoietic stem and progenitor cells), potentially representing a novel therapeutic approach for recruiting HSPCs prior to ABMT (autologous bone marrow transplantation). ATI-2341 also induces chemotaxis in CCRF-CEM cells, exhibiting the characteristic bell-shaped curve observed with chemotactic agents[1]. |
| In vivo | Intraperitoneal (i.p.) injection of ATI-2341 in BALB/c mice results in a dose-dependent recruitment of PMNs into the peritoneum, with a maximal effect seen at 405 nmol/kg. A higher concentration of ATI-2341 results in reduced recruitment, which is reminiscent of the bell-shaped curve generally seen with chemotactic agents. Intravenous (i.v.) administration of ATI-2341 in mice results in a dose-dependent increase in PMNs in the peripheral circulation, measured 90 min after administration of compound. The effect is maximal at 0.66 μMol/kg of ATI-2341. ATI-2341 has no effect on the mobilization of lymphocytes at any dose tested[1]. |
| Cell Research | Receptors(CXCR4-eGFP) are transiently transfected into HEK-293 cells and are plated 24 h after transfection on glass coverslips coated with poly-D-lysine. The next day, cells are treated with either vehicle alone or with varying concentrations of ATI-2341 for 30 min at 37 °C followed by fixation with methanol for 5 min at −20 °C. GFP fluorescence is visualized directly using a Zeiss Axiovert inverted microscope. Images are processed using Adobe Photoshop and Adobe Illustrator. (Only for Reference) |
| Synonyms | ATI2341 |
| Molecular Weight | 2256.82 |
| Formula | C104H178N26O25S2 |
| Cas No. | 1337878-62-2 |
| Smiles | [C@@H](CC1=CC=C(O)C=C1)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=C(O)C=C2)NC(CNC([C@@H](NC(CCCCCCCCCCCCCCC)=O)CCSC)=O)=O)=O)CCC(N)=O)=O)CCCCN)=O)CCCCN)=O)CC(C)C)=O)CCCNC(=N)N)=O)CO)=O)CCSC)=O)[C@@H](C)O)=O)CC(O)=O)=O)CCCCN)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(O)=O)=O)CCCNC(=N)N)=O |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Sequence | palmitoyl-Met-Gly-Tyr-Gln-Lys-Lys-Leu-Arg-Ser-Met-Thr-Asp-Lys-Tyr-Arg-Leu-OH |
| Sequence Short | 1-Oxohexadecyl-MGYQKKLRSMTDKYRL |
| Storage | keep away from moisture,store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol: 2 mg/mL (0.89 mM), Sonication is recommended. DMSO: 93 mg/mL (41.21 mM), Sonication is recommended. H2O: <1 mg/mL |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.